Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata (NR3C1 and AA)

March 3, 2026 updated by: karem Taha ibrahim khalil, Benha University

Assessment of Glucocorticoid Receptor Gene Polymorphism in Alopecia Areata

Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Qalyubia Governorate
      • Banhā, Qalyubia Governorate, Egypt, 13511
        • Benha University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study will include 60 patients clinically diagnosed with alopecia areata and 60 age- and sex-matched healthy controls recruited from the same geographic area.

Description

Inclusion Criteria (Cases):

  • Clinically diagnosed alopecia areata
  • Age ≥ 18 years
  • Both sexes
  • Willingness to participate and provide informed consent

Inclusion Criteria (Controls):

  • Apparently healthy individuals
  • No history of autoimmune disease
  • Age- and sex-matched to cases
  • Provided informed consent

Exclusion Criteria:

  • Presence of other autoimmune or inflammatory diseases
  • Current systemic immunosuppressive therapy
  • Pregnancy or lactation
  • Refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1: Alopecia Areata Patients
Participants diagnosed clinically with alopecia areata (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. Disease severity will be assessed using SALT score.
Group 2: Healthy Controls
Age- and sex-matched healthy individuals without autoimmune disease (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Distribution of NR3C1 rs41423247 Genotypes and Alleles
Time Frame: Baseline
Comparison of genotype and allele frequencies of NR3C1 rs41423247 polymorphism between alopecia areata patients and healthy controls.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association Between NR3C1 rs41423247 Polymorphism and Disease Severity
Time Frame: Baseline
Correlation between NR3C1 rs41423247 genotypes and Severity of Alopecia Tool (SALT) score in patients with alopecia areata.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Benha University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2023

Primary Completion (Actual)

November 1, 2024

Study Completion (Actual)

December 1, 2024

Study Registration Dates

First Submitted

March 3, 2026

First Submitted That Met QC Criteria

March 3, 2026

First Posted (Actual)

March 6, 2026

Study Record Updates

Last Update Posted (Actual)

March 6, 2026

Last Update Submitted That Met QC Criteria

March 3, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Ms 10.9.2023
  • Benha faulty of medicine (Registry Identifier: Ms 10.9.2023)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alopecia Areata(AA)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe